Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Selective liver targeting of antivirals by recombinant chylomicrons — a new therapeutic approach to hepatitis B

Abstract

Hepatitis B virus (HBV) infection is the world's most important chronic virus infection. No safe and effective treatment is available at present, and clinical exploration of promising antiviral agents, such as nucleoside analogues is hampered because of significant side-effects due to their aspecific body distribution. We are exploring the possibility of the selective delivery of antiviral active drugs to liver parenchymal cells, the main site of infection and replication of HBV. Chylomicrons, which transport dietary lipids into the liver via apolipoprotein E-specific receptors, could serve as drug carriers. However, their endogenous nature hampers their application as pharmaceutical drug carriers. We report here that incorporation of a derivative of the nucleoside analogue iododeoxy-uridine into recombinant chylomicrons leads to selective targeting to liver parenchymal cells. Potentially effective intracellular drug concentrations of 700 nM can be achieved, and we therefore anticipate that these drug carrier complexes represent a conceptual advance in the development of an effective and safe therapy for hepatitis B.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Tiollais, P., Pourcel, C. & Dejean, A. The hepatitis B virus. Nature (London) 317, 489–495 (1985).

    Article  CAS  Google Scholar 

  2. Yoffe, B. & Noonan, C.A. Hepatitis B virus: new and evolving issues. Digest. Dis. Sci. 37, 1–9 (1992).

    Article  CAS  Google Scholar 

  3. Beasley, R.P., Hwang, L.Y., Lin, C.C. & Chien, C.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 2, 1129–1133 (1981).

    Article  CAS  Google Scholar 

  4. Beasley, R.P. The major etiology of hepatocellular carcinoma. Cancer 61, 1942–1956 (1988).

    Article  CAS  Google Scholar 

  5. Ueda, K., Tsurimoto, T., Nagahata, T., Chisaka, O. & Matsubara, K., An in vitro system for screening anti-hepatitis B virus drugs. Virology 169, 213–216 (1989).

    Article  CAS  Google Scholar 

  6. Weller, I.V.D. et al. Acyclovir inhibits hepatitis B virus replication in man. J. antimicrob. Chemother. 11, 223–231 (1983).

    Article  CAS  Google Scholar 

  7. Hoofnagle, J.H. et al. Randomized control trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 86, 150–157 (1984).

    Article  CAS  Google Scholar 

  8. Lok, A.S.F., Wilson, L.A. & Thomas, H.C. Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection. J. antimicrob. Chemother. 14, 93–99 (1984).

    Article  CAS  Google Scholar 

  9. Summers, J. & Mason, W.S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29, 403–115 (1982).

    Article  CAS  Google Scholar 

  10. Seeger, C., Ganem, D. & Varmus, H.E. Biochemical and genetic evidence for the hepatitis B replication strategy. Science 232, 477–484 (1986).

    Article  CAS  Google Scholar 

  11. Mahley, R.W. & Hussain, M.M. Chylomicron and chylomicron remnant catabolism. Carr. Opin. Lipidol. 2, 170–176 (1991).

    Article  CAS  Google Scholar 

  12. Hoeg, J.M., Demosky, S.J. Jr, Gregg, R.E., Schaefer, E.J. & Brewer, H.B. Jr Distinct hepatic receptors for low density lipoprotein and apolipoprotein E in humans. Science 227, 759–761 (1985).

    Article  CAS  Google Scholar 

  13. Bijsterbosch, M.K. & van Berkel, Th.J.C. Native and modified lipoproteins as drug delivery systems. Adv. Drug Delivery Rev. 5, 231–251 (1990).

    Article  CAS  Google Scholar 

  14. Shaw, J.M. ed Lipoproteins as carriers of pharmaceutical agents (Marcel Dekker, Inc, New York, 1991).

    Google Scholar 

  15. Van Dijk, M.C.M. et al. Recognition of chylomicron remnants and β-migrating very-low-density lipoproteins by the remnant receptor of parenchymal liver cells is distinct from the liver α2-macroglobulin-recognition site. Biochem. J. 279, 863–870 (1991).

    Article  CAS  Google Scholar 

  16. Mahley, R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622–630 (1988).

    Article  CAS  Google Scholar 

  17. Windier, E., Chao, Y.S. & Havel, R.J. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat: opposing effects of homologous apolipoprotein E and individual C apoproteins. J. Boil. Chem. 255, 8303–8307 (1980).

    Google Scholar 

  18. Van Berkel, Th.J.C., Kruijt, J.K., Scheek, L.M. & Groot, P.H.E. Effect of apolipoproteins E and C-III on the interaction of chylomicrons with parenchymal and non-parenchymal cells from rat liver. Biochem. J. 216, 71–80 (1983).

    Article  CAS  Google Scholar 

  19. Vogel, T. et al. Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E. Proc. natn. Acad. Sci. U.S.A. 82, 8696–8700 (1985).

    Article  CAS  Google Scholar 

  20. Huettinger, M., Retzek, H., Eder, M. & Goldenberg, H. Characteristics of chylomicron remnant uptake into rat liver. Clin. Biochem. 21, 87–92 (1988).

    Article  CAS  Google Scholar 

  21. Chen, Z., Keech, A. et al. Prolonged infection with hepatitis B virus and association between low blood cholesterol concentration and liver cancer. Brit. med. J. 306, 890–894 (1993).

    Article  CAS  Google Scholar 

  22. Price, P.M., Banerjee, R. & Acs, G. Inhibition of the replication of hepatitis B virus by the carbocyclic analog of 2′-deoxyguanosine. Proc. natn. Acad. Sci. U.S.A. 86, 8543–8544 (1989).

    Google Scholar 

  23. Lin, T.S. et al. Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J. med. Chem. 37, 798–803 (1994).

    Article  CAS  Google Scholar 

  24. Summers, J., Smolec, J.M. & Snyder, R. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc. natn. Acad. Sci. U.S.A. 75, 4533–4537 (1978).

    Article  CAS  Google Scholar 

  25. Tennant, B.D. & Gerin, J.L. The woodchuck model of hepatitis B virus infection. In: The Liver: Biology and Pathobiology (eds. Arias, I.M. et al.) 1455–1466 (Raven, New York 1994).

    Google Scholar 

  26. Périgaud, C., Gosselin, G. & Imbach, J.L. Nucleoside analogues as chemotherapeutic agents; a review. Nucleos. Nucleot. 11, 903–945 (1992).

    Article  Google Scholar 

  27. Sacks, S.L. et al. Toxicity of vidarabine. JAMA 241, 28–29 (1979).

    Article  CAS  Google Scholar 

  28. Sacks, S.L. et al. Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination. Antimicrob. Agents Chemother. 21, 93–100 (1982).

    Article  CAS  Google Scholar 

  29. Redgrave, T.G. & Maranhao, R.C. Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim. biophys. Acta. 835, 104–112 (1985).

    Article  CAS  Google Scholar 

  30. Bijsterbosch, M.K., Schouten, D. & van Berkel, Th.J.C. Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry 33, 14073–14080 (1994).

    Article  CAS  Google Scholar 

  31. Bijsterbosch, M.K., Ziere, G.J. & van Berkel, Th.J.C. Lactosylated low density lipoprotein: a potential carrier for the site-specific delivery of drugs to Kupffer cells. Mol. Pharmacol. 36, 484–489 (1989).

    CAS  PubMed  Google Scholar 

  32. Van Berkel, Th.J.C., Dekker, C.J., Kruijt, J.K. & van Eijk, H.G. The interaction in vivo of transferrin and asialotransferrin with liver cells. Biochem. J. 243, 715–722 (1987).

    Article  CAS  Google Scholar 

  33. Blouin, A., Bolender, R.D. & Weibel, E.R. Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma: a stereological study. J. Cell. Biol. 72, 441–455 (1977).

    Article  CAS  Google Scholar 

  34. Nagelkerke, J.F., Barto, K.P. & van Berkel, Th.J.C. In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer and parenchymal cells. J. biol. Chem. 258, 12221–12227 (1983).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rensen, P., Van Dijk, M., Havenaar, E. et al. Selective liver targeting of antivirals by recombinant chylomicrons — a new therapeutic approach to hepatitis B. Nat Med 1, 221–225 (1995). https://doi.org/10.1038/nm0395-221

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0395-221

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing